Literature DB >> 31082873

Incidence of Advanced Colorectal Neoplasia in Individuals With Untreated Diminutive Colorectal Adenomas Diagnosed by Magnifying Image-Enhanced Endoscopy.

Masau Sekiguchi1,2,3, Yosuke Otake1,4, Yasuo Kakugawa3, Minori Matsumoto3, Yutaka Tomizawa5, Yutaka Saito3, Takahisa Matsuda1,2,3.   

Abstract

OBJECTIVES: Because of the increasing number of detected diminutive colorectal adenomas, the "diagnose-and-do-not-resect" approach has recently attracted attention as an alternative to resection. We evaluated the cumulative incidence of advanced colorectal neoplasia (ACN) in individuals with untreated diminutive adenomas and compared this incidence in individuals without adenomas.
METHODS: Data from 1,378 individuals who underwent first screening colonoscopy (CS) and at least one follow-up CS without polypectomy were analyzed. Patients with no adenomas or with only nonadvanced diminutive adenomas (<5 mm) diagnosed by magnifying image-enhanced endoscopy were scheduled to undergo a follow-up CS within 5 years after the initial CS without treatment. The participants were divided into 2 groups: those with untreated diminutive adenomas (group A) and those with no adenomas (group B). The cumulative incidence of ACN and the hazard ratio were assessed using Gray's test and the Fine and Gray model.
RESULTS: During the median follow-up period of 60.9 months, 21 ACNs were detected. The 5-year cumulative incidences of ACN in group A (n = 361) and group B (n = 1,017) were 1.4% (95% confidence interval [CI]: 0.5-3.4) and 0.8% (95% CI: 0.3-1.7), respectively, without a statistically significant difference (P = 0.23). No ACNs developed from unresected adenomas. The smoking status was significantly associated with the incidence of ACN, and the hazard ratio for ACN in group A vs group B adjusted for smoking status was 1.43 (95% CI: 0.52-3.90; P = 0.48). DISCUSSION: The low 5-year cumulative incidence of ACN suggests the potential to adopt the "diagnose-and-do-not-resect" strategy as an alternative option for diminutive adenomas not requiring excessive surveillance.

Entities:  

Mesh:

Year:  2019        PMID: 31082873     DOI: 10.14309/ajg.0000000000000261

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

1.  Randomised comparison of postpolypectomy surveillance intervals following a two-round baseline colonoscopy: the Japan Polyp Study Workgroup.

Authors:  Takahisa Matsuda; Takahiro Fujii; Yasushi Sano; Shin-Ei Kudo; Yasushi Oda; Kinichi Hotta; Tadakazu Shimoda; Yutaka Saito; Nozomu Kobayashi; Masau Sekiguchi; Kazuo Konishi; Hiroaki Ikematsu; Hiroyasu Iishi; Yoji Takeuchi; Masahiro Igarashi; Kiyonori Kobayashi; Miwa Sada; Yuichiro Yamaguchi; Kiwamu Hasuda; Tomoaki Shinohara; Hideki Ishikawa; Yoshitaka Murakami; Hirokazu Taniguchi; Takahiro Fujimori; Yoichi Ajioka; Shigeaki Yoshida
Journal:  Gut       Date:  2020-11-02       Impact factor: 23.059

2.  British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines.

Authors:  Matthew D Rutter; James East; Colin J Rees; Neil Cripps; James Docherty; Sunil Dolwani; Philip V Kaye; Kevin J Monahan; Marco R Novelli; Andrew Plumb; Brian P Saunders; Siwan Thomas-Gibson; Damian J M Tolan; Sophie Whyte; Stewart Bonnington; Alison Scope; Ruth Wong; Barbara Hibbert; John Marsh; Billie Moores; Amanda Cross; Linda Sharp
Journal:  Gut       Date:  2019-11-27       Impact factor: 31.793

3.  Outcomes at follow-up of negative colonoscopy in average risk population: systematic review and meta-analysis.

Authors:  Thomas Heisser; Le Peng; Korbinian Weigl; Michael Hoffmeister; Hermann Brenner
Journal:  BMJ       Date:  2019-11-13

Review 4.  Post-polypectomy surveillance: the present and the future.

Authors:  Masau Sekiguchi; Takahisa Matsuda; Kinichi Hotta; Yutaka Saito
Journal:  Clin Endosc       Date:  2022-07-11

5.  Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening.

Authors:  Masau Sekiguchi; Takahisa Matsuda
Journal:  Sci Rep       Date:  2020-10-23       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.